Corzide 40/5 Pregnancy Warnings
This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.
US FDA pregnancy category: C
Animal studies with bendroflumethiazide have not been reported. Animal studies with nadolol have revealed evidence of embryotoxicity and fetotoxicity, but no teratogenicity. In humans, neonates whose mothers received nadolol at parturition exhibited bradycardia, hypoglycemia, and associated symptoms. There are no controlled data in human pregnancy.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
See references
